Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MiMARK’s lead product, WomEC, is an in vitro diagnostic test for endometrial cancer using a panel of protein biomarkers from uterine fluid. The test aims to provide a non-invasive “rule-out” option with high sensitivity (~99%) and specificity (~87%), potentially replacing invasive hysteroscopies. As of mid–2025, the device is completing prototyping and entering clinical validation stages. No commercial or pivotal trial results have been published yet.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MiMARK Diagnostics.